PMID- 17350463
OWN - NLM
STAT- MEDLINE
DCOM- 20070411
LR  - 20101118
IS  - 0165-4608 (Print)
IS  - 0165-4608 (Linking)
VI  - 174
IP  - 1
DP  - 2007 Apr 1
TI  - Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate 
      cancer.
PG  - 24-34
AB  - Although Knudson's two-hit hypothesis with functional loss of a tumor suppressor 
      gene has been widely accepted, accumulating evidence suggests that several genes 
      are regulated by the quantity of their product in a dose-dependent manner (gene 
      dosage effect). The study was designed to identify the influence of gene dosage 
      effect of 8p22 on patient prognosis. With a median age of 71 years, 40 patients 
      with prostate cancer (11 organ-confined, 13 capsular penetrating, and 16 nodal 
      and/or distant metastatic) were followed for a median of 68.5 months. A 
      fluorescence in situ hybridization (FISH) technique was applied using a 
      region-specific cosmid probe combined with centromeric probe. Allelic losses of 
      8p22, 8p21.3, 8p21.1 approximately 2, and 8p12 were found in 23, 22, 14, and 9 
      patients, respectively. A Cox proportional hazard model revealed that decreased 
      fraction (i.e., the fraction of nuclei with a lesser number of cosmid signals 
      than of centromeric probe signals) of 8p22 proved to be the sole independent 
      prognostic factor predicting cancer-specific death, as well as disease 
      progression--but allelic loss of 8p22 was not predictive. Cytogenetic estimation 
      of 8p22 by FISH can yield quantitative evaluation of relevant gene dosage, which 
      may become a useful biomolecular marker predicting poor patient prognosis.
FAU - Matsuyama, Hideyasu
AU  - Matsuyama H
AD  - Department of Urology, Yamaguchi University School of Medicine, 1-1-1 
      Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan.
FAU - Oba, Kazuo
AU  - Oba K
FAU - Matsuda, Kenji
AU  - Matsuda K
FAU - Yoshihiro, Satoru
AU  - Yoshihiro S
FAU - Tsukamoto, Manabu
AU  - Tsukamoto M
FAU - Kinjo, Mitsuru
AU  - Kinjo M
FAU - Sagiyama, Kazuyuki
AU  - Sagiyama K
FAU - Takei, Mineo
AU  - Takei M
FAU - Yamaguchi, Akito
AU  - Yamaguchi A
FAU - Sasaki, Kohsuke
AU  - Sasaki K
FAU - Naito, Katsusuke
AU  - Naito K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosomes, Human, Pair 8/*genetics
MH  - Gene Dosage/*genetics
MH  - Genome, Human/genetics
MH  - Haploidy
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Loss of Heterozygosity/genetics
MH  - Male
MH  - Metaphase
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prostate/pathology
MH  - Prostatic Neoplasms/*genetics/pathology
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2007/03/14 09:00
MHDA- 2007/04/12 09:00
CRDT- 2007/03/14 09:00
PHST- 2006/09/01 00:00 [received]
PHST- 2006/10/30 00:00 [revised]
PHST- 2006/11/03 00:00 [accepted]
PHST- 2007/03/14 09:00 [pubmed]
PHST- 2007/04/12 09:00 [medline]
PHST- 2007/03/14 09:00 [entrez]
AID - S0165-4608(06)00735-7 [pii]
AID - 10.1016/j.cancergencyto.2006.11.008 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2007 Apr 1;174(1):24-34. doi: 
      10.1016/j.cancergencyto.2006.11.008.